N
Nt-Comnwlth Super Corp
+ HältSGP
-1.91%
3-Monats-Rendite
$24.600
+0.615 (+2.50%)Zum Schluss
Loading chart…
- Hoch
- 25.150
- Eröffnung
- 24.360
- Volumengewichteter Durchschnittskurs
- 24.70
- Volumen
- 69.78K
- Marktkap.
- —
- Tief
- 24.338
- Umsatz
- 1.72M
- EV/EBITDA, TTM
- 0.00
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
KI-Analyse of SpyGlass Pharma Inc (SGP)
VerkaufenSpyGlass Pharma, Inc. is not a good buy right now due to its significant net losses and poor technical indicators. The stock is currently priced at $24.00, with a 5-day change of -3.69% and a 20-day change of -17.47%. The RSI is at 39.059, indicating that the stock is nearing oversold territory, but the overall trend remains negative. The company reported a net loss of $19.9 million for Q2 2026, which is a substantial increase from previous losses, highlighting ongoing financial struggles. The main risk is the continued increase in expenses, particularly R&D and administrative costs, which could further impact profitability.
Bewertungskennzahlen
Das aktuelle erwartete KGV von SpyGlass Pharma Inc (SGP) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von .
Whales, die SGP halten
Event-Zeitleiste
News
9.508-19Yahoo FinanceStockland Reports 10.4% FFO Growth in Latest Earnings
4.508-14Yahoo FinanceCPI and PPI Data Spark Market Rally
9.508-06NASDAQ.COMSpyGlass Pharma Reports Wider Q2 Net Loss Amid Rising Expenses
9.505-15seekingalphaSpyGlass Pharma Reports Q1 Financial Results
- 8.503-26seekingalpha
SpyGlass Pharma Reports Q4 Earnings and IPO Details
SGP FAQ – beantwortet von Alphio AI
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye. It operates in the Healthcare sector.
SpyGlass Pharma, Inc. is not a good buy right now due to its significant net losses and poor technical indicators. The stock is currently priced at $24.00, with a 5-day change of -3.69% and a 20-day change of -17.47%. The RSI is at 39.059, indicating that the stock is nearing oversold territory, but the overall trend remains negative. The company reported a net loss of $19.9 million for Q2 2026, which is a substantial increase from previous losses, highlighting ongoing financial struggles. The main risk is the continued increase in expenses, particularly R&D and administrative costs, which could further impact profitability.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.